Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 3.32% and Operating profit at -24.33% over the last 5 years
2
With a growth in Operating Profit of 129.09%, the company declared Outstanding results in Sep 25
3
With ROE of 4.15%, it has a fair valuation with a 2.46 Price to Book Value
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,163 Million (Mid Cap)
59.00
NA
0.34%
0.45
5.15%
1.39
Revenue and Profits:
Net Sales:
812 Million
(Quarterly Results - Mar 2026)
Net Profit:
42 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-18.4%
0%
-18.4%
6 Months
-17.07%
0%
-17.07%
1 Year
-2.79%
0%
-2.79%
2 Years
1.61%
0%
1.61%
3 Years
-22.23%
0%
-22.23%
4 Years
-39.62%
0%
-39.62%
5 Years
-68.83%
0%
-68.83%
Zhejiang Tianyu Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.32%
EBIT Growth (5y)
-24.33%
EBIT to Interest (avg)
25.90
Debt to EBITDA (avg)
3.71
Net Debt to Equity (avg)
0.48
Sales to Capital Employed (avg)
0.46
Tax Ratio
11.00%
Dividend Payout Ratio
30.77%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.24%
ROE (avg)
4.61%
Valuation key factors
Factor
Value
P/E Ratio
59
Industry P/E
Price to Book Value
2.46
EV to EBIT
62.26
EV to EBITDA
20.62
EV to Capital Employed
1.97
EV to Sales
3.70
PEG Ratio
0.10
Dividend Yield
0.19%
ROCE (Latest)
3.17%
ROE (Latest)
4.15%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
811.70
774.20
4.84%
Operating Profit (PBDIT) excl Other Income
65.20
32.50
100.62%
Interest
9.50
9.60
-1.04%
Exceptional Items
-0.20
0.70
-128.57%
Consolidate Net Profit
42.20
-81.20
151.97%
Operating Profit Margin (Excl OI)
80.30%
-76.20%
15.65%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 4.84% vs 7.60% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 151.97% vs -213.73% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
3,042.20
2,621.90
16.03%
Operating Profit (PBDIT) excl Other Income
559.20
444.20
25.89%
Interest
45.70
56.00
-18.39%
Exceptional Items
-7.30
12.00
-160.83%
Consolidate Net Profit
139.70
55.90
149.91%
Operating Profit Margin (Excl OI)
65.40%
41.30%
2.41%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 16.03% vs 4.40% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 149.91% vs 104.01% in Dec 2024
About Zhejiang Tianyu Pharmaceutical Co., Ltd. 
Zhejiang Tianyu Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






